CD274 and non-small cell lung carcinoma: Results from the CITYSCAPE Phase II trial of anti-TIGIT tiragolumab and atezolizumab in patients with PD-L1+ advanced NSCLC demonstrated grade >=3 TRAE in 15% of patients.